PolyPid (PYPD) Non-Current Debt (2022 - 2025)
PolyPid (PYPD) posted Non-Current Debt of $381000.0 for Q1 2025, down 39.91% sequentially from $634000.0 in Q4 2024, and down 91.11% YoY from $4.3 million in Q1 2024.
PolyPid (PYPD) Non-Current Debt (2022 - 2025) Analysis & Trends
PolyPid has reported Non-Current Debt for 4 years, with the latest figure at $381000.0 in Q1 2025.
- Quarterly Non-Current Debt fell 91.11% year-over-year to $381000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $381000.0 (down 91.11% YoY) and the FY2024 annual result came in at $634000.0, down 90.06% from the prior year.
- Non-Current Debt declined to $381000.0 in Q1 2025 per PYPD's latest filing, from $634000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $8.5 million in Q2 2023 and troughed at $381000.0 in Q1 2025.
- A 4-year average of $5.3 million and a median of $6.6 million in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2023 and 2025: Non-Current Debt advanced 23.4% in 2023, then plunged 91.11% in 2025.
- Over 4 years, Non-Current Debt stood at $7.6 million in 2022, then decreased by 15.78% to $6.4 million in 2023, then sank by 90.06% to $634000.0 in 2024, then plunged by 39.91% to $381000.0 in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $381000.0, $634000.0, and $2.5 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | PolyPid | 113.30 Mn | 106.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 381,000.00 |
| Dec 31, 2024 | 634,000.00 |
| Sep 30, 2024 | 2.53 Mn |
| Jun 30, 2024 | 3.13 Mn |
| Mar 31, 2024 | 4.29 Mn |
| Dec 31, 2023 | 6.38 Mn |
| Sep 30, 2023 | 7.67 Mn |
| Jun 30, 2023 | 8.54 Mn |
| Mar 31, 2023 | 6.76 Mn |
| Dec 31, 2022 | 7.57 Mn |
| Sep 30, 2022 | 8.35 Mn |
| Jun 30, 2022 | 6.92 Mn |